Bristol's University Hospitals haematology department manages ITP patients from across the South West of England. For Bristol patients not accessing NHS Eltromopag through specialist commissioning, or those seeking private supply, Eltromag 25mg provides the same clinical efficacy as Promacta and Revolade at dramatically reduced cost.
Bristol's significant South Asian community from the city's historical ties to Bristol's diverse Easton and St Pauls neighbourhoods accesses haematology services at Bristol Royal Infirmary and Southmead Hospital. Affordable Eltromag removes financial barriers to long-term ITP management for Bristol's full diverse community regardless of socioeconomic status.
Visit medshopy.com or WhatsApp +91 82650 41513 for Bristol supply.
Bristol's significant South Asian community from the city's historical ties to Bristol's diverse Easton and St Pauls neighbourhoods accesses haematology services at Bristol Royal Infirmary and Southmead Hospital. Affordable Eltromag removes financial barriers to long-term ITP management for Bristol's full diverse community regardless of socioeconomic status.
Visit medshopy.com or WhatsApp +91 82650 41513 for Bristol supply.
Rituximab is a monoclonal antibody targeting CD20, a protein on B-lymphocytes — the cells that produce the anti-platelet antibodies driving ITP. By depleting B-cells, rituximab can induce remission in some ITP patients, with approximately 40-60% responding initially. The advantage of rituximab is that some patients achieve durable remissions lasting a year or more — and unlike TPO-RAs which only raise platelet counts while you take them, rituximab can produce off-treatment responses. The limitation is that responses are less predictable and many patients relapse within 1-2 years. In UK clinical practice, rituximab is typically used after first-line steroids fail and before or alongside TPO-RAs like Eltromag — the sequencing depends on individual patient factors, response history, and Bristol haematologist preference. It's generally considered a second-line option alongside TPO-RAs rather than a required step before them.
